Product Images Losartan Potassium
View Photos of Packaging, Labels & Appearance
Product Label Images
The following 6 images provide visual information about the product associated with Losartan Potassium NDC 68645-599 by Legacy Pharmaceutical Packaging, Llc, such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.
PACKAGE LABEL.PRINCIPAL DISPLAY PANEL - LOSARTAN POTASSIUM 5OMG
This is a description of a medication product containing Losartan Potassium. Each tablet is NDC 68645-599-54 with 50mg strength. The product should be stored between 20-25°C and should be protected from light. The medication is distributed by a manufacturer and it is dispensed without a patient information leaflet. The container should be sealed tightly and the medication should be handled with care. The product is packaged by Legacy Pharmaceutical Packaging LLC.*
Chemical Structure - spl image1 structure1
Figure 1 - spl image2 figure1
The text describes a study that compares Atenolol and Losartan Potassium in terms of their efficacy in reducing the primary endpoint in patients. The study lasted for 66 months and showed an adjusted risk reduction of 13% with a p-value of 0.021.*
Figure 2 - spl image3 figure2
This text appears to be a comparison between two medications, Atenolol and Losartan Potassium, where the adjusted risk reduction for a particular outcome is 25% with a significance level of p=0.001. The graph shows the percentage of patients who experienced a fatal/non-fatal stroke over a period of 66 study months, with measurements taken at every 6-month interval.*
Figure 3 - spl image4 figure3
The text describes a table (Figure 3) that presents the number of primary endpoint events for patients in demographic subgroups in a clinical trial. The primary endpoint is a composite of fatal/non-fatal stroke, and the patients received either Losartan Potassium or Atenolol. The table presents the number of events, event rate (%), and Hazard Ratio (95% CI) for each subgroup, categorized by age, gender, race, ISH, diabetes, and history of CVD. The table also includes symbols proportional to sample size and explains that "other" includes Asian, Hispanic, Asiatic, Multi-race, Indian, Native American, European. The results are adjusted for the baseline Framingham risk score and level of electrocardiographic left ventricular hypertrophy.*
Figure 4 - spl image5 figure4
This appears to be a graph showing the % of patients with an event in a study comparing Losartan Potassium to Placebo over a period of 48 months. It also indicates that there was a risk reduction of 16.1% with a p-value of 0.022.*
* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.